206 related articles for article (PubMed ID: 28649601)
21. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.
Jenner P
Acta Neurol Scand Suppl; 1993; 146():6-13. PubMed ID: 8333254
[TBL] [Abstract][Full Text] [Related]
22. Iron and dopamine: a toxic couple.
Hare DJ; Double KL
Brain; 2016 Apr; 139(Pt 4):1026-35. PubMed ID: 26962053
[TBL] [Abstract][Full Text] [Related]
23. Nigral diffusivity, but not free water, correlates with iron content in Parkinson's disease.
Langley J; Huddleston DE; Hu X
Brain Commun; 2021; 3(4):fcab251. PubMed ID: 34805996
[TBL] [Abstract][Full Text] [Related]
24. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?
Andersen JK
Novartis Found Symp; 2001; 235():11-20; discussion 20-5. PubMed ID: 11280021
[TBL] [Abstract][Full Text] [Related]
25. Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson's disease.
Riederer P; Monoranu C; Strobel S; Iordache T; Sian-Hülsmann J
J Neural Transm (Vienna); 2021 Oct; 128(10):1577-1598. PubMed ID: 34636961
[TBL] [Abstract][Full Text] [Related]
26. Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease.
Khedher L; Bonny JM; Marques A; Durand E; Pereira B; Chupin M; Vidal T; Chassain C; Defebvre L; Carriere N; Fraix V; Moro E; Thobois S; Metereau E; Mangone G; Vidailhet M; Corvol JC; Lehéricy S; Menjot de Champfleur N; Geny C; Spampinato U; Meissner W; Frismand S; Schmitt E; Doé de Maindreville A; Portefaix C; Remy P; Fénelon G; Luc Houeto J; Colin O; Rascol O; Peran P; Durif F;
Neuroimage Clin; 2022; 36():103231. PubMed ID: 36279753
[TBL] [Abstract][Full Text] [Related]
27. Modulation effect of substantia nigra iron deposition and functional connectivity on putamen glucose metabolism in Parkinson's disease.
Zang Z; Song T; Li J; Yan S; Nie B; Mei S; Ma J; Yang Y; Shan B; Zhang Y; Lu J
Hum Brain Mapp; 2022 Aug; 43(12):3735-3744. PubMed ID: 35471638
[TBL] [Abstract][Full Text] [Related]
28. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease.
Jin L; Wang J; Jin H; Fei G; Zhang Y; Chen W; Zhao L; Zhao N; Sun X; Zeng M; Zhong C
Eur J Neurol; 2012 Jul; 19(7):969-76. PubMed ID: 22288465
[TBL] [Abstract][Full Text] [Related]
29. Interplay of Ferritin Accumulation and Ferroportin Loss in Ageing Brain: Implication for Protein Aggregation in Down Syndrome Dementia, Alzheimer's, and Parkinson's Diseases.
Raha AA; Biswas A; Henderson J; Chakraborty S; Holland A; Friedland RP; Mukaetova-Ladinska E; Zaman S; Raha-Chowdhury R
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162984
[TBL] [Abstract][Full Text] [Related]
30. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy.
Griffiths PD; Dobson BR; Jones GR; Clarke DT
Brain; 1999 Apr; 122 ( Pt 4)():667-73. PubMed ID: 10219780
[TBL] [Abstract][Full Text] [Related]
31. Ageing and Parkinson's disease: why is advancing age the biggest risk factor?
Reeve A; Simcox E; Turnbull D
Ageing Res Rev; 2014 Mar; 14(100):19-30. PubMed ID: 24503004
[TBL] [Abstract][Full Text] [Related]
32. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease.
Du G; Lewis MM; Styner M; Shaffer ML; Sen S; Yang QX; Huang X
Mov Disord; 2011 Aug; 26(9):1627-32. PubMed ID: 21618607
[TBL] [Abstract][Full Text] [Related]
33. In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease.
Gonzalez-Sepulveda M; Compte J; Cuadros T; Nicolau A; Guillard-Sirieix C; Peñuelas N; Lorente-Picon M; Parent A; Romero-Giménez J; Cladera-Sastre JM; Laguna A; Vila M
Brain; 2023 Mar; 146(3):1040-1052. PubMed ID: 36717986
[TBL] [Abstract][Full Text] [Related]
34. Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson's Disease on Brain Networks.
Wen J; Guo T; Wu J; Bai X; Zhou C; Wu H; Liu X; Chen J; Cao Z; Gu L; Pu J; Zhang B; Zhang M; Guan X; Xu X
J Parkinsons Dis; 2022; 12(8):2479-2492. PubMed ID: 36336939
[TBL] [Abstract][Full Text] [Related]
35. Different iron deposition patterns in early- and middle-late-onset Parkinson's disease.
Xuan M; Guan X; Gu Q; Shen Z; Yu X; Qiu T; Luo X; Song R; Jiaerken Y; Xu X; Huang P; Luo W; Zhang M
Parkinsonism Relat Disord; 2017 Nov; 44():23-27. PubMed ID: 28838722
[TBL] [Abstract][Full Text] [Related]
36. Complex I, iron, and ferritin in Parkinson's disease substantia nigra.
Mann VM; Cooper JM; Daniel SE; Srai K; Jenner P; Marsden CD; Schapira AH
Ann Neurol; 1994 Dec; 36(6):876-81. PubMed ID: 7998774
[TBL] [Abstract][Full Text] [Related]
37. Quantitative evaluation of brain iron accumulation in different stages of Parkinson's disease.
Li KR; Avecillas-Chasin J; Nguyen TD; Gillen KM; Dimov A; Chang E; Skudin C; Kopell BH; Wang Y; Shtilbans A
J Neuroimaging; 2022 Mar; 32(2):363-371. PubMed ID: 34904328
[TBL] [Abstract][Full Text] [Related]
38. What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?
Youdim MB
J Neural Transm Suppl; 2003; (65):73-88. PubMed ID: 12946050
[TBL] [Abstract][Full Text] [Related]
39. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
40. Different iron deposition patterns in akinetic/rigid-dominant and tremor-dominant Parkinson's disease.
Xiong W; Li LF; Huang L; Liu Y; Xia ZC; Zhou XX; Tang BS; Guo JF; Lei LF
Clin Neurol Neurosurg; 2020 Nov; 198():106181. PubMed ID: 33022525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
